1. Extracorporeal shock wave lithotripsy is safe and effective for pediatric patients with chronic pancreatitis
- Author
-
Di Zhang, Jun-Tao Ji, Ting-Ting Du, Wen-Bin Zou, Bai-Rong Li, Jun Pan, Xiang-Peng Zeng, Zhao-Hong Zheng, Ya-Wei Bi, Zhuan Liao, Zhao-Shen Li, Hui Chen, Lei Xin, Liang-Hao Hu, Dan Wang, Ting Xie, Bo Ye, and Jin-Huan Lin
- Subjects
Adult ,Male ,medicine.medical_specialty ,Stone clearance ,Adolescent ,Health Status ,medicine.medical_treatment ,Lithiasis ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Lithotripsy ,Pancreatitis, Chronic ,medicine ,Humans ,Pancreatic stones ,Prospective Studies ,Young adult ,Child ,Prospective cohort study ,Pain Measurement ,Cholangiopancreatography, Endoscopic Retrograde ,business.industry ,Gastroenterology ,Middle Aged ,medicine.disease ,Extracorporeal shock wave lithotripsy ,Abdominal Pain ,Surgery ,Mental Health ,Child, Preschool ,030220 oncology & carcinogenesis ,Quality of Life ,Pancreatitis ,Female ,030211 gastroenterology & hepatology ,Observational study ,business ,Follow-Up Studies - Abstract
Background and aims Pancreatic extracorporeal shock wave lithotripsy (P-ESWL) is recommended as the first-line treatment for pancreatic stones. However, how well P-ESWL performs in pediatric patients remains unclear. We aimed to evaluate the safety and efficacy of P-ESWL for pediatric patients with chronic pancreatitis. Methods This prospective observational study was conducted in patients with painful chronic pancreatitis who underwent P-ESWL. Patients aged under 18 years were included in the pediatric group; patients aged over 18 years who underwent P-ESWL in the same period were assigned to the control group. For investigation of long-term follow-up, the pediatric group were matched with patients from the control group in a 1:1 ratio. The primary outcomes were P-ESWL complications and pain relief. The secondary outcomes included: stone clearance, physical and mental health, quality of life score, and growth and developmental state. Results From March 2011 to March 2015, P-ESWL was performed in 1135 patients (72 in the pediatric group, 1063 in the control group). No significant differences were observed in the occurrence of P-ESWL complications between the two groups (11.1 % vs. 12.8 %; P = 0.68). Among the 67 pediatric patients (93.1 %) who underwent follow-up for 3.0 years (range 1.3 – 5.2), complete pain relief was achieved in 52 patients (52 /67; 77.6 %); this value was not significantly different from that of the matched controls (55 /69; 79.7 %; P = 0.94). Conclusions P-ESWL is safe and effective for pediatric patients with chronic pancreatitis. It can promote significant pain relief and stone clearance, and can benefit growth and development.
- Published
- 2017